CTOs on the Move

ImmPACT Bio USA

www.immpact-bio.com

 
ImmPACT-Bio is pioneering a novel strategy to surmount a major challenge compromising current Chimeric Antigen Receptor T-cell (CAR-T) therapy. Our technology addresses the need to differentiate cancerous from non-cancerous tissues impacting the safety of the treatment which is to date a major limitation in reaching effectiveness.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Sylvain Roy
Chief Technology Officer Profile

Funding

ImmPACT Bio USA raised $18M on 08/18/2020

Similar Companies

Cleave Biosciences

Cleave Biosciences is a biopharmaceutical company pioneering the development of novel protein homeostasis inhibitors for the treatment of cancer.

MCR Labs

Have your medicine tested at MCR Labs, an ISO-17025 accredited cannabis testing laboratory. We test cannabis products for harmful contaminants and provide cannabinoid profiling. A test requires 0.25 to 0.5 grams flower, 0.1 to 0.2 grams concentrate...

Irvine Scientific

Irvine Scientific is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.